Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and
50mg tid in active rheumatoid arthritis patients unsuccessfully treated with
disease-modifying antirheumatic drug.